AUROPHARMA.NSAUROPHARMA.NSNSE
Loading
Year-over-year earnings per share growth rate
3Y CAGR
-28.5%/yr
vs +187.2%/yr prior
5Y CAGR
-51.3%/yr
Recent acceleration
Acceleration
-215.7pp
Decelerating
Percentile
P69
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 7.26% |
| Q3 2025 | 2.89% |
| Q2 2025 | -8.74% |
| Q1 2025 | 6.87% |
| Q4 2024 | 4.00% |
| Q3 2024 | -10.77% |
| Q2 2024 | 1.16% |
| Q1 2024 | -3.30% |
| Q4 2023 | 25.02% |
| Q3 2023 | 31.72% |
| Q2 2023 | 12.73% |
| Q1 2023 | 3.10% |
| Q4 2022 | 19.89% |
| Q3 2022 | -21.28% |
| Q2 2022 | -9.76% |
| Q1 2022 | -4.65% |
| Q4 2021 | -13.20% |
| Q3 2021 | -9.51% |
| Q2 2021 | -3.88% |
| Q1 2021 | -72.82% |
| Q4 2020 | 265.75% |
| Q3 2020 | 3.23% |
| Q2 2020 | -9.63% |
| Q1 2020 | 22.43% |
| Q4 2019 | 10.26% |
| Q3 2019 | 0.65% |
| Q2 2019 | 8.61% |
| Q1 2019 | -17.78% |
| Q4 2018 | 16.38% |
| Q3 2018 | 34.19% |
| Q2 2018 | -13.75% |
| Q1 2018 | -11.22% |
| Q4 2017 | -23.78% |
| Q3 2017 | 50.62% |
| Q2 2017 | -2.75% |
| Q1 2017 | -7.89% |
| Q4 2016 | -5.09% |
| Q3 2016 | 4.20% |
| Q2 2016 | -3.76% |
| Q1 2016 | 13.32% |